Dexmedetomidine-based intravenous sedation of a Glucose-6-phosphate dehydrogenase deficiency pediatric patient: A case report Nanae Takahashi ¹⁾ Takashi Ogawa ²⁾ Yuichi Sato ¹⁾ Masato Takahashi ³⁾ Tomoka Matsumura ¹⁾ Haruhisa Fukayama ⁴⁾ and Akibumi Omi ¹⁾

 ¹⁾ Department of Anesthesiology, ²⁾Department of Oral and Maxillofacial Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
³⁾ Department of Oral and Maxillofacial Surgery, Kamagaya General Hospital, Chiba, Japan
⁴⁾ Department of Anesthesiology and Clinical Physiology, Tokyo Medical and Dental University, Tokyo, Japan

Introduction

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a very common X-linked genetic disorder caused by a structural abnormality in the G6PD enzyme. The G6PD enzyme catalyzes the first step in the pentose phosphate pathway, leading to antioxidants that protect red-blood-cells against oxidative damage. (Fig. 1)G6PD deficiency can cause hemolytic anemia, usually after exposure to certain medications, foods, and infections. Therefore, clinical management of G6PD deficiency is to prevent hemolysis caused by oxidant stress from certain drugs, and severe infections. To the best of our knowledge, this is the first reported case of dexmedetomidine-based intravenous sedation used in a G6PD deficiency patient.

Fig. 1. Pentose-phosphate pathway



Patient and Methods Patient

The patient was a 5-year-old boy (height 115 cm, body weight 22 kg) with G6PD deficiency. (Fig. 2.) He had no previous medical history of hemolytic anemia. He did not have any problems when he took painkillers or cold medicines. The patient's grandfather, who was of Taiwanese origin, also had G6PD deficiency; however, the grandfather also had never developed a hemolytic reaction. (Fig. 3) The patient had mild amblyopia and a mild mental retardation. We performed frenectomy under intravenous sedation. **Methods**

We used dexmedetomidine-based intravenous sedation. Dexmedetomidine has been reported to have antioxidant activity, to cause less respiratory depression than other sedatives, and to be effective for pediatric sedation. And, we used other sedative drugs before using dexmedetomidine, to avoid a change in circulation at the time of dexmedetomidine loading. His vital signs were stable and maintained a Ramsay Score of 4.

Lancet 2008; 371: 64-74

Fig. 2. Patient's G6PD enzyme data



Anesthesia Chart

Allestilesta Ullart		
Time 10:):00	11:00
O_2 (L/min)) 3	
2% Xylocaine (1/80,000 E)(ml)		
Fentanyl (µg)	25	
Midazolam (mg)) 1 1	
Dexmedetomidine (µg/kg/h)	0.7	
$\operatorname{SpO2}$	2 99 100 100 100 100 100 100	
Respiration rate (min)) 24 22 22 22 22 22	
Transfusion (mL)		
HR (Hart rate) • (udq) Systolic pressure • 80		
Systolic pressure $\sqrt{\frac{1}{60}}$ 80	0	

rig. 4. wind classificat	tion of G6PD deficiency
Class I Severely deficie	nt chronic hemolytic anemia
Class II 1%-10% residua	l activity Our patient
Class III 10%-60% residu	al activity
Class IV 60%-150% norm	nal activity
Class V $>150\%$ increase	ed activity
variants of GOLD deficiency	are grouped into 5 classes based
their enzyme activity and clin Bull World Health Organ 198	
their enzyme activity and clin	nical manifestations.

HN-

(antipyretic or



Results

During dexmedetomidine-based intravenous sedation, good respiratory and circulatory states were maintained. No problems occurred in the perioperative period; signs of hemolysis such as fatigue, headache, and dark urine were not observed.

Conclusions

Our case suggests that the selection and use of sedatives with anti-oxidant and anti-inflammatory effects to counter the rise in perioperative oxidative stress will increase safety. Dexmedetomidine was safe and effective for this pediatric patient with G6PD deficiency. We suggest that dexmedetomidine is a safe drugs that can be used for pediatric patients with G6PD deficiency.

References

M D Cappellini,G Fiorelli .Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008;371:64-74

Philip J Mason et al. G6PD deficiency: the genotype-phenotype association. Blood Reviews 2007;21:267-283

Elyassi AR Rowshan HH. Perioperative management of the glucose-6-phosphate dehydrogenase deficient patient: areview of literature. Anesth Prog;2009;56:86-91